Neurogene Inc.
Neurogene Inc. (NGNE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · NGNE · as of Sep 30, 2025
Ownership Breakdown
90
Institutional Holders
▲ 5 vs Q2
$265.17M
Total Inst. Value
▲ $35.05M vs Q2
15.80M
Shares Outstanding
freeFloat 79.30%
15.30M
13F Shares Held
▼ 89,423 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
NGNE largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SAMSARA BIOCAPITAL, LLC pharmaceutical preparations | 1.72M | 8.16% | 8.16% | $29.76B | Nov 14, 2025 | — held |
RTW INVESTMENTS, LP pharmaceutical preparations | 1.36M | 6.47% | 6.47% | $23.61B | Nov 14, 2025 | — held |
REDMILE GROUP, LLC pharmaceutical preparations | 1.30M | 6.17% | 6.17% | $22.51B | Nov 14, 2025 | ▲ 22.3K |
CASDIN CAPITAL, LLC pharmaceutical preparations | 1.30M | 6.15% | 6.15% | $22.45B | Nov 14, 2025 | — held |
ECOR1 CAPITAL, LLC pharmaceutical preparations | 1.27M | 6.04% | 6.04% | $22.03B | Nov 14, 2025 | — held |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 991.7K | 4.71% | 4.71% | $17.19B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 951.1K | 4.52% | 4.52% | $16.48B | Nov 12, 2025 | ▼ 26.6K |
BALYASNY ASSET MANAGEMENT L.P. pharmaceutical preparations | 699.0K | 3.32% | 3.32% | $12.11B | Nov 14, 2025 | NEW |
TORONTO DOMINION BANK pharmaceutical preparations | 681.3K | 3.24% | 3.24% | $11.81B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 604.6K | 2.87% | 2.87% | $10.48B | Nov 7, 2025 | ▼ 5.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
11
Increased
+341.9K shares9
New Positions
first time holders18
Decreased
−843.1K shares0
Sold Out
fully exitedNet shares change (top 50)
501.2K
+341.9K / −843.1K
Net new holders
+2
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
NGNE insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
2
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Cvijic Christine Mikail President and CFO | May 6, 2026 | Sale | 4,800 | $30.07 | $144.4K | 98.4K | Form 4 ↗ |
Cvijic Christine Mikail President and CFO | May 6, 2026 | Sale | 4,800 | $32.44 | $155.7K | 93.6K | Form 4 ↗ |
Shafer Christina Chief Commercial Officer | May 5, 2026 | Award | 120,000 | $28.94 | $3.47M | 120.0K | Form 4 ↗ |
Cvijic Christine Mikail President and CFO | Mar 26, 2026 | Sale | 2,558 | $21.62 | $55.3K | 103.2K | Form 4 ↗ |
McMinn Rachel Chief Executive Officer | Mar 26, 2026 | Sale | 3,352 | $22.07 | $74.0K | 1.34M | Form 4 ↗ |
Jordan Julie Chief Medical Officer | Mar 26, 2026 | Sale | 828 | $21.89 | $18.1K | 12.5K | Form 4 ↗ |
Cobb Stuart Chief Scientific Officer | Mar 13, 2026 | Sale | 3,991 | $20.41 | $81.5K | 33.3K | Form 4 ↗ |
Cobb Stuart Chief Scientific Officer | Mar 13, 2026 | Sale | 2,658 | $21.34 | $56.7K | 30.6K | Form 4 ↗ |
Cobb Stuart Chief Scientific Officer | Mar 13, 2026 | Sale | 148 | $22.08 | $3.3K | 30.5K | Form 4 ↗ |
Cvijic Christine Mikail President and CFO | Mar 13, 2026 | Sale | 2,387 | $20.42 | $48.7K | 107.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Neurogene Inc. (NGNE) is primarily owned by institutional investors, who hold approximately 96.8% of total shares outstanding. Company insiders own approximately 20.70%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Neurogene Inc. is SAMSARA BIOCAPITAL, LLC, holding approximately 1.72 million shares — equal to 8.16% of outstanding shares — as of September 30, 2025.
A total of 90 institutional investors currently hold NGNE stock, with a combined institutional value of approximately $265,173,378 as of the most recent 13F filing period.
Frequently asked questions
NGNE ownershipNeurogene Inc. (NGNE) is primarily owned by institutional investors, who hold approximately 96.8% of shares. The largest shareholder is SAMSARA BIOCAPITAL, LLC with a 8.16% stake. Company insiders hold 20.70%. Data sourced from SEC Form 13F as of September 30, 2025.